BioMarin Pharmaceutical Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $2.77B | $408.3M |
| FY2017 | — | $2.81B | $598.0M |
| FY2018 | — | $2.97B | $494.0M |
| FY2019 | — | $3.12B | $437.4M |
| FY2020 | — | $4.10B | $649.2M |
| FY2021 | — | $4.27B | $587.3M |
| FY2022 | — | $4.60B | $724.5M |
| FY2023 | — | $4.95B | $755.1M |
| FY2024 | — | $5.66B | $942.8M |
| FY2025 | — | $6.09B | $1.31B |